Antithrombin III inhibits nuclear factor κB activation in human monocytes and vascular endothelial cells

Blood

Volumn 99, Issue 11, 2002, Pages 4015-4020

  Oelschläger, Christian ^a,b   Römisch, Jürgen ^a,b   Staubitz, Anne ^a,b   Stauss, Harald ^a,b   Leithäuser, Boris ^a,b   Tillmanns, Harald ^a,b   Hölschermann, Hans ^a,b  

^a JUSTUS LIEBIG UNIVERSITY GIESSEN   (Germany)

^b SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN III; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

ARTICLE; BINDING KINETICS; CONTROLLED STUDY; ENDOTHELIUM CELL; GENE ACTIVATION; HUMAN; HUMAN CELL; MOLECULAR DYNAMICS; MONOCYTE; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DNA INTERACTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION;

EID: 0036625064     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V99.11.4015     Document Type: Article

References (35)

1. Bauer KA, Rosenberg RD. Role of antithrombin III as a regulator of in vivo coagulation. Semin Hematol. 1991;28:10-18.
2. Emerson TE Jr, Fournel MA, Redens TB, Taylor FB Jr. Efficacy of antithrombin III supplementation in animal models of fulminant Escherichia coli endotoxemia or bacteremia. Am J Med. 1989;87(suppl B3):27S-33S.
3. Dickneite G, Leithäuser B. Influence of antithrombin III on coagulation and inflammation in porcine septic shock. Arterioscler Thromb Vasc Biol. 1999;19:1566-1572.
4. Meijer C, Wiezer MJ, Hack CE, et al. Coagulopathy following major liver resection: The effect of and the role of decreased synthesis of regulating proteins by liver. Shock. 2001;15:261-271.
5. Inthorn D, Hoffmann JN, Hartl WH, Mühlbayer D, Jochum M. Antithrombin III supplementation in severe sepsis: Beneficial effects on organ dysfunction. Shock. 1997;8:238-334.
6. Inthorn D, Hoffmann JN, Hartl WH, Mülbayer D, Jochum M. Effect of antithrombin III supplementation on inflammatory immune response in patients with severe sepsis. Shock. 1998;10:90-96.
7. Eisele B, Larmy M, Thijs LG, et al. Antithrombin III in patients with severe sepsis. A randomized, placebo-controlled, double-blind multicenter trial plus a meta-analysis on all randomized, placebo-controlled, double-blind trials with antithrombin III in severe sepsis. Intensive Care Med. 1998;24:663-672.
8. Hoffmann JN, Vollmar B, Inthorn D, Schildberg FW, Menger MD. Antithrombin reduces leukocyte adhesion during chronic endotoxemia by modulation of the cyclooxygenase pathway. Am J Physiol Cell Physiol. 2000;279:C98-C107.
9. Kurose I, Miura S, Funkumura D, et al. Attenuating effect of antithrombin III on the fibrinolytic activation and microvascular derangement in rat gastric mucosa. Thromb Haemost. 1994;71:119-123.
10. Ostrovsky L, Woodman RC, Payne D, Teoh D, Kubes P. Antithrombin III prevents and rapidly reverses leukocyte recruitment in ischemia/reperfusion. Circulation. 1997;96:2302-2310.
11. Harada N, Okajima K, Kushimoto S, Isobe H, Tanaka K. Antithrombin reduces ischemia/reperfusion injury of rat liver by increasing the hepatic level of prostacyclin. Blood. 1999;93:157-164.
12. Uchiba M, Okajima K, Murakami K, Okabe H, Takatsuki K. Attenuation of endotoxin-induced pulmonary vascular injury by antithrombin III. Am J Physiol. 1996;270;L921-L930.
13. Totzke G, Smolny M, Seibel M, Czechowski M, Schobersbergher W, Hoffmann G. Antithrombin III enhances inducible NOS gene expression in vascular smooth muscle cells. Cell Immunol. 2001;208:1762-1770.
14. Dunzendorfer S, Kaneider N, Rabensteiner A, et al. Cell-surface heparan sulfate proteoglycan-mediated regulation of human neutrophil migration by the serpin antithrombin III. Blood. 2001;97:1079-1085.
15. Souter PJ, Thomas S, Hubbard AR, Poole S, Römisch J, Gray E. Antithrombin inhibits lipopoly-saccharide-induced tissue factor and interleukin-6 production by mononuclear cells, human umbilical vein endothelial cells, and whole blood. Crit Care Med. 2001;29:134-139.
16. Yamamoto Y, Gaynor RB. Therapeutic potential of inhibition of the NF-kappa B pathway in the treatment of inflammation and cancer. J Clin Invest. 2001;107:135-142.
17. Hatata EN, Krappmann D, Scheidereit C. NF-κB and the innate immune response. Curr Opin Immunol. 2000;12:52-58.
18. Peters RT, Maniatis T. A new family of IKK-related kinases may function as I kappa B kinase kinases. Biochim Biophys Acta. 2001;1471:M57-M62.
19. Karin M, Delhase M. The I kappa B kinase (IKK) and NF-kappa B: Key elements of proinflammatory signalling. Semin Immunol. 2000;12:85-98.
20. Höschermann H, Dürfeld F, Maus U, et al. Cyclo-sporine A inhibits tissue factor expression in monocytes/macrophages. Blood. 1996;88:3837-3845.
21. Jaffe EA, Nachman RL, Becker CG, et al. Culture of human endothelial cells derived from umbilical veins: Identification of morphologic and immunologic criteria. J Clin Invest. 1973;52:2745-2756.
22. Blackburn MN, Smith RL, Carson J, Sibley CC. The heparin-binding site of antithrombin III. Identification of a critical tryptophan in the amino acid sequence. J Biol Chem. 1984;259:939-941.
23. Hölschermann H, Rascher C, Oelschläger C, et al. Opposite regulation of tissue factor by calcineurin in monocytes and endothelial cells. J Immunol. 2001;166:7112-7120.
24. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanatephenol-chloroform extraction. Anal Biochem. 1987;162:156-159.
25. Scarpati EM, Wen D, Broze G, et al. Human tissue factor: cDNA-sequence and chromosome localisation of the gene. Biochemistry. 1987;26:5234-5238.
26. Opal SM. Phylogenetic and functional relationships between coagulation and the innate immune response. Crit Care Med. 2000;28(suppl 9):S77-S80.
27. Cirino G, Bucci M, Cicala C, Napoli C. Inflammation-coagulation network: Are serine protease receptors the knot? Trends Pharmacol Sci. 2000;21:170-172.
28. Coughlin SR. Thrombin signalling and protease-activated receptors. Nature. 2000;407:258-264.
29. Esmon CT. Introduction: Are natural anticoagulants candidates for modulating the inflammatory response to endotoxin? Blood. 2000;95:1113-1116.
30. Jochum M. Influence of high-dose antithrombin concentrate therapy on the release of cellular proteinases, cytokines, and soluble adhesion molecules in acute inflammation. Semin Hematol. 1995;32(suppl 2):19-32.
31. Zuo XJ, Okada Y, Nicolaidou E, et al. Antithrombin III inhibits T- and B-lymphocyte activation in vitro and improves parameters of inflammation in a rat model of acute lung allograft rejection. Transplant Proc. 1999;31:816-817.
32. Rao LV, Nordfang O, Hoang AD, Pendurthi UR. Mechanism of antithrombin III inhibition of factor VIIa/tissue factor activity on cell surfaces. Comparison with tissue factor pathway inhibitor/factor Xa-induced inhibition of factor VIIa/tissue factor activity. Blood 1995;85:121-129.
33. Minnema MC, Chang ACK, Jansen PM, et al. Recombinant human antithrombin III improves survival and attenuates inflammatory responses in baboons lethally challenged with Escherichia coli. Blood 2000;95:1117-1123.
34. Warren BL, Eid A, Singer P, et al. High-dose anti-thrombin III in severe sepsis. A randomized controlled trial. JAMA 2001;286:1869-1878.
35. Picard V, Ersdal-Badju E, Bock SC. Partial glycosylation of antithrombin III asparagine-135 is caused by the serine in the third position of its N-glycosylation consensus sequence and is responsible for production of the beta-antithrombin III with enhanced heparin affinity. Biochemistry 1995;34:8433-8440.